Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.630
-0.500 (-15.97%)
At close: Jan 14, 2025, 4:00 PM
2.550
-0.080 (-3.04%)
After-hours: Jan 14, 2025, 7:58 PM EST
Soligenix Revenue
Soligenix had revenue of $364.18K in the twelve months ending September 30, 2024, down -62.09% year-over-year. In the year 2023, Soligenix had annual revenue of $839.36K, down -11.55%.
Revenue (ttm)
$364.18K
Revenue Growth
-62.09%
P/S Ratio
8.63
Revenue / Employee
$24,279
Employees
15
Market Cap
6.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
SNGX News
- 16 hours ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 6 weeks ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 2 months ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 2 months ago - Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - PRNewsWire
- 2 months ago - Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - PRNewsWire